- Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
- Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
- Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
More ▼
Key statistics
On Tuesday, ACADIA Pharmaceuticals Inc (ACAD:NSQ) closed at 18.19, 25.02% above the 52 week low of 14.55 set on Jun 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.01 |
---|---|
High | 18.44 |
Low | 18.01 |
Bid | 17.60 |
Offer | 18.52 |
Previous close | 18.13 |
Average volume | 2.04m |
---|---|
Shares outstanding | 165.22m |
Free float | 164.38m |
P/E (TTM) | -- |
Market cap | 3.00bn USD |
EPS (TTM) | -0.0129 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 21:15 BST.
More ▼